Mannkind, Game-Chancer in Sachen Diabetik? (Seite 14)

[Magnetfeldfredy]

Mannkind

Durch den Megaerfolg mit DPI Tyvaso, das Mannkind in der Spitze bis zu 100 Millionen US Dollar pro Jahr einbringen wird, ist es für die Technosphere Technology ein proof of concept und big pharma wird sicher zweistellig bieten müssen, ich tippe auf UTHR, dann bleibt alles im Haus, Produkiton DPI Tyvaso, Pramien......
Ich tippe auf US Dollar 15 pro Aktie!
Falls nicht stehen neben Afrezza nach die orale Cannabidoil Behandlung für panische Angst auf dem Radar, wo der Partner RLS jetzt schon klinische Tests startet, noch ein Milliardenmarkt!

[Signal999]

Antwort auf Beitrag Nr.: 72.720.359 von price-of-success am 09.11.22 16:51:56

Naja, falls es zu einer Übernahme käme wäre das U.U.gar nicht so schlecht.Am Besten wenn der Wert bei den besagten 6,50$ wäre.
Da währen die Verluste beim Panther erträglicher und würden nicht so Schmerzen.

[price-of-success]

bereits. typo.

[Signal999]

Antwort auf Beitrag Nr.: 72.720.128 von price-of-success am 09.11.22 16:23:57

Moin.Was sind herrits?

[price-of-success]

sind aktuell herrits über 4 USd

[price-of-success]

moin
evtl kauft jemand Mannkind auf
mit der Technik ist das durchaus denkbar
imo

[Magnetfeldfredy]

Mannkind

KZ 6,50 US Dollar



QUICK LINKS :
Goldman Sachs Conviction Buy List
Warren Buffett News
Elliott Associates News

Analyst Comments, Analyst EPS View
Get it on Google Play
Cantor Fitzgerald Reiterates Overweight Rating on MannKind (MNKD); '3Q22 A Vote of Confidence in Long-Term Outlook'
Article
Stock Quotes (1)
Close

FREE Breaking News Alerts from StreetInsider.com!
E-mail Address

StreetInsider.com Top Tickers, 11/9/2022
1. DOX
2. DIS
3. AFRM
4. UPST
5. GO
6. LCID
7. AKAM
8. SFM
9. CG
10. CARG

Top News
Most Read
Special Reports

Futures edge lower as race for control over Congress tightens
Elon Musk sells $3.95 billion worth of Tesla (TSLA) shares
Zuckerberg confirms Meta (META) will cut 11,000 jobs
Race for U.S. Congress is tight, no Republican 'red wave'
Walt Disney (DIS) stock falls 7% after earnings miss, analysts remain cautious


November 8, 2022 12:37 PM EST
Tweet Share E-mail

Get Alerts
MNKD Hot Sheet
Price: $3.81 --0%

Rating Summary:
8 Buy, 3 Hold, 6 Sell

Rating Trend: = Flat

Today's Overall Ratings:
Up: 12 | Down: 25 | New: 8
Join SI Premium – FREE
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cantor Fitzgerald analyst Brandon Folkes reiterated an Overweight rating and $6.50 price target on MannKind (NASDAQ: MNKD) following Q3 results, calling them a "vote of confidence in the long-term outlook."

The analyst commented, "United Therapeutics (UTHR, Not Covered) announced in May the approval of Tyvaso DPI, for which MNKD will receive royalties as well as manufacture. UTHR launched commercial efforts shortly thereafter, its first commercial shipments to specialty pharmacies occurred in June 2022 and the first patients started Tyvaso DPI therapy shortly thereafter. We view UTHR as having a strong start to the initial launch of Tyvaso DPI, and this was evidenced by the strong 3Q22 results that MNKD presented today. While still in the early stages of Tyvaso DPI launch, we are encouraged by the start, as well as MNKD's strong balance sheet, solid pipeline and commercial execution, especially V-Go, while Afrezza continues to grow both total and new prescriptions double-digit (on a y/y basis).

Going forward, we believe data readouts from the company's own pipeline and better-than-forecast revenue could drive further upside in MNKD stock."

For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.

Shares of MannKind closed at $3.63 yesterday.

[Magnetfeldfredy]

Mnkd

Bestes Quartal ever, Tyvase DPI rockt die Bude bei unserem Partner UTHR und wir werden bald zweistellig:

MannKind Corporation Reports 2022 Third Quarter Financial Results

MannKind
Tue, November 8, 2022 at 2:00 PM
In this article:

MNKD
+4.96%
Watchlist

Patternyahoo plus badge
Bullish
trade type L

MannKind
MannKind

Conference Call to Begin Today at 9:00 a.m. (ET)

3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 2021

3Q 2022 Royalties from Tyvaso DPI of $6.2 million

3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third quarter and nine months ended September 30, 2022.

“In the third quarter, we grew total revenues by 48% over 2021 as our collaboration with United Therapeutics had its first full quarter during which we recognized both manufacturing revenue and royalties associated with the launch of Tyvaso DPI,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “In addition, our Endocrine Business Unit grew revenues 67% over 2021 as we integrated the V-Go acquisition and continued to grow Afrezza demand.”

Third Quarter 2022 Results

Total revenues were $32.8 million for the third quarter of 2022, reflecting Afrezza® net revenue of $10.8 million, V-Go® net revenue of $5.4 million, collaborations and services revenue of $10.3 million, and royalties of $6.2 million. Afrezza net revenue increased 11% compared to $9.8 million in the third quarter of 2021 as a result of price (including a more favorable gross-to-net adjustment) and higher patient demand, partially offset by wholesaler inventory ordering patterns which resulted in lower inventory levels for the third quarter of 2022. Collaborations and services revenue decreased $2.1 million compared to the third quarter of 2021 primarily due to the completion of the research and development (“R&D”) services associated with our collaboration with United Therapeutics (“UT”), which was mostly offset by manufacturing revenue from sales of Tyvaso DPI® to UT following the launch of Tyvaso DPI in June 2022.

Afrezza gross profit for the third quarter of 2022 was $8.7 million compared to $5.9 million in the same period of 2021, an increase of $2.8 million, or 47%, which was driven by an increase in Afrezza sales and a decrease in cost of goods sold. Afrezza’s cost of goods sold decreased by $1.7 million, or 45%, compared to the same period in 2021, primarily due to a $2.0 million decrease in excess capacity costs. Afrezza gross margin in the third quarter of 2022 was 81% compared to 61% for the same period in 2021. V-Go gross profit for the third quarter of 2022 was $2.5 million with a gross margin of 46%.

Cost of revenue – collaborations and services in the third quarter of 2022 was $12.4 million compared to $6.1 million for the same period in 2021, an increase of $6.4 million, primarily due to an increase in manufacturing activities for the production of Tyvaso DPI.

R&D expenses for the third quarter of 2022 were $4.1 million compared to $3.6 million for the third quarter of 2021. This $0.5 million increase was mainly related to personnel costs for headcount hired in the second half of 2021, partially offset by a decrease in the Afrezza pediatrics clinical study (INHALE-1) due to study startup costs incurred in the third quarter of 2021.

Selling, general and administrative (“SG&A”) expenses for the third quarter of 2022 were $22.6 million compared to $17.2 million for the third quarter of 2021. This $5.4 million increase was primarily attributable to V-Go promotional efforts, the elimination of a co-promotion collaboration (which permitted some expenses associated with the sales force to be recognized as cost of revenue for collaborations and services in the third quarter of 2021), higher stock-based compensation, the net impact of personnel-related costs due to Afrezza sales force restructuring and increased professional fees.

For the third quarter of 2022, the gain on foreign currency translation (for insulin purchase commitments denominated in Euros) was $1.8 million compared to $2.1 million for the third quarter of 2021. The fluctuation was due to a change in the U.S. dollar to Euro foreign currency exchange rate.

Interest income, consisting of interest on investments net of amortization, increased $0.6 million for the third quarter of 2022 to $0.7 million primarily due to higher yields on our marketable securities and money market funds.

Interest expense on the financing liability was $2.5 million for the third quarter of 2022, representing interest incurred on the November 2021 sale and lease-back of our manufacturing facility in Danbury, CT.

The net loss for the third quarter of 2022 was $14.4 million, or $0.06 per share, compared to $4.4 million in the third quarter of 2021, or $0.02 per share. The $10.0 million increase in net loss was primarily due to an increase in selling, general and administrative expense, interest on the financing liability, and the $4.9 million gain on extinguishment of debt in the third quarter of 2021.

Nine Months September 30, 2022

Total revenues were $63.7 million for the nine months ended September 30, 2022, reflecting Afrezza net revenue of $31.3 million, V-Go net revenue of $7.5 million, collaborations and services revenue of $18.4 million and royalties of $6.5 million. Afrezza net revenue increased 13% compared to $27.8 million in the nine months ended September 30, 2021 as a result of price (including a more favorable gross-to-net adjustment) higher product demand and a more favorable cartridge mix. Collaborations and services revenue for the nine months ended September 30, 2022 decreased $16.7 million compared to the same period in the prior year, primarily due to the completion of the R&D services associated with our collaboration with UT, which was partially offset by revenues associated with Tyvaso DPI of $15.8 million. As of September 30, 2022, $32.2 million of revenue associated with UT remains deferred and will be recognized as commercial product is sold to UT.

Afrezza gross profit for the nine months ended September 30, 2022 was $23.6 million, compared to $15.3 million in the same period of 2021, an increase of $8.3 million, or 54%, which was driven by an increase in Afrezza sales and a decrease in cost of goods sold. Afrezza’s cost of goods sold for the nine months ended September 30, 2022 decreased by $4.8 million, or 38%, compared to the same period in 2021, primarily due to a $3.8 million decrease in excess capacity costs and a $2.0 million fee incurred for the amendment of the Insulin Supply Agreement in the prior year period. Afrezza gross margin for the nine months ended September 30, 2022 was 75% compared to 55% for the same period in 2021. V-Go gross profit for the nine months ended September 30, 2022 was $3.3 million with a gross margin of 44%.

Cost of revenue – collaborations and services for the nine months ended September 30, 2022 was $29.5 million compared to $14.9 million for the same period in 2021, an increase of $14.6 million, primarily due to an increase in manufacturing activities for the production of Tyvaso DPI.

R&D expenses for the nine months ended September 30, 2022 were $12.6 million compared to $8.4 million for the same period in 2021. This $4.2 million increase was primarily attributable to personnel costs for headcount hired in the second half of 2021, development activities on our product pipeline, and the Afrezza pediatrics clinical study (INHALE-1).

SG&A expenses for the nine months ended September 30, 2022 were $69.4 million compared to $54.7 million for the same period in 2021. This $14.7 million increase was primarily attributable to a pilot promotional effort aimed at primary care physicians that began in Q4 2021, elimination of a co-promotion collaboration (which permitted some expenses associated with the sales force to be recognized as cost of revenue from collaborations and services in the same period of 2021), promotional expenses to support V-Go, higher stock-based compensation and increased professional and consulting fees.

For the nine months ended September 30, 2022, the gain on foreign currency translation (for insulin purchase commitments denominated in Euros) was $8.3 million compared to $5.0 million for the same period of 2021. The fluctuation was due to a change in the U.S. dollar to Euro foreign currency exchange rate.

Interest income, consisting of interest on investments net of amortization, increased $1.5 million for the nine months ended September 30, 2022 to $1.6 million primarily due to higher yields on our marketable securities and money market funds.

Interest expense on the financing liability was $7.3 million for the nine months ended September 30, 2022, representing interest incurred on the November 2021 sale and lease-back of our manufacturing facility in Danbury, CT.

The net loss for the nine months ended September 30, 2022 was $69.5 million, or $0.27 per share, compared to $52.9 million in the same period of 2021, or $0.21 per share. The $16.6 million increase in the net loss was primarily due to higher cost of revenue for collaborations and services due to increased manufacturing activities for Tyvaso DPI, higher selling, general and administrative expenses, interest on the financing liability and increased research and development expenses, offset by a $17.2 million loss on the extinguishment of debt in 2021.

As of September 30, 2022, cash and cash equivalents and investments were $177.8 million.

Conference Call

MannKind will host a conference call and presentation webcast to discuss these results today at 9:00 a.m. Eastern Time. Those interested in listening to the conference call live via the Internet may do so by visiting the Company’s website at mannkindcorp.com under Events & Presentations. A replay will be available on MannKind's website for 14 days.

[Signal999]

Die Ergebnisse und Nachrichten klingen gut

und stimmen optimistisch.
Bin jetzt seit 11 Jahren dabei und noch mit 15% im Minus.Waren aber auch schon einmal 92%
Damals ging mir mächtig der Frack, aber jetzt geht's da es stetig bergauf geht.
Viel Glück allen Investierten.

[price-of-success]

noch Verlust
trotzdem
läuft gut in den Augen der Kollegen in den USA